Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...
German biotech firm's revenues down 27% compared to 2023, according to company's financial report - Anadolu Ajansı ...
Ugur Sahin, the co-founder and CEO of BioNTech SE (BNTX), sold $119.58 million worth of the Germany-based biotechnology company’s stock last week. This is the first big Informative Sell ...
Reports Q4 revenue EUR 1.19B vs. EUR 1.48B last year. “From the very beginning, BioNTech’s (BNTX) vision has been to translate our science into ...
She has a Neutral rating and price target of $110. BioNTech’s founders, Ugur Sahin, the CEO, and his wife, Ozlem Tureci, the ...
"We expect 2025 to be a data-rich year with multiple important updates from our priority programs," said Chief Executive Ugur Sahin. BioNTech forecast revenue between 1.7 billion euros and 2.2 billion ...
Hosted on MSN10mon
What's Going With BioNTech Stock On Monday?We look forward to providing more updates this year across our oncology portfolio, including our bispecific antibody and ADC programs,” said Ugur Sahin, CEO and Co-Founder of BioNTech.
Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's fourth quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback